HOT: DIAGNOSIS AND TREATMENT OF INFECTION RELATED ARTHRITIDES

Robert Schoen, Yale School of Medicine, Rheumatology, Allergy, Clinical Immunology, New Haven, United States of America

Background: Management of infectious arthritis has evolved because of empirical knowledge, clinical studies, and emerging pathogens. For patients with bacterial arthritis, organism specific, effective anti-microbial therapy is essential, but assessment of co-morbidities, adequate joint drainage, and supportive care are also required. For patients with infectious arthritis an acute intervention is usually necessary, since delay in diagnosis often leads to unsatisfactory outcome. In some situations, the distinction between infection and a post-infectious inflammatory process may be challenging.

Objectives: The goal of this lecture is to review management of septic arthritis in native joints. In addition, I will discuss Lyme arthritis and chronic chikungunya arthritis as examples of the broadening spectrum of infectious arthritis.

Methods: This lecture will rely on my clinical experience and a Pubmed literature search.

Results: In this HOT lecture, I will provide practical, up to date information about the diagnosis and management of septic (bacterial) arthritis of native joints. I will discuss longstanding treatment paradigms, as well as advances in management and areas of uncertainty. I will then consider two emerging infections, Lyme arthritis and chronic chikungunya arthritis, that illustrate the changing spectrum of infectious arthritis.

Conclusion: It is the intention of this lecture to assist rheumatologists in management of patients across the spectrum of infectious arthritis. Accurate diagnosis and treatment are often challenging, but critical to satisfactory patient outcome.

REFERENCES:

Disclosure of Interests: None declared

FRIDAY, 14 JUNE 2019

Safety First! Infectious complications and pregnancy issues in patients with rheumatic diseases

Catherine Nelson-Piercy, Guy’s and St. Thomas’ Foundation Trust and Queen Charlotte’s and Chelsea Hospital London, United Kingdom

Pregnancy issues in patients with rheumatic diseases: the OB perspective for rheumatologists

Learning Objectives:
- Understand the importance of pre pregnancy counselling for women with rheumatic disease in pregnancy
- Understand the risk factors for adverse pregnancy outcome in women with rheumatic disease
- Understand the medications which are compatible with use in pregnancy and lactation
- Understand the management of rheumatic disease in pregnancy

Abstract: Rheumatic disease predominantly affects women of child-bearing age and are commonly encountered in obstetric practice. Pregnancy poses an important challenge for doctors looking after these women. Knowledge about medication safety, the effect of pregnancy on the disease, and vice versa, together with pre-conception counselling and multidisciplinary team care, are important to provide the best obstetric and medical care to these women.

Women with rheumatic have increased risks of miscarriage, preterm delivery, pre-eclampsia, fetal growth restriction, and disease flare in pregnancy. The main risk factor for adverse pregnancy outcomes in inflammatory arthritis is active disease flare. For women with SLE the risks are lupus nephritis, particularly with CKD class 3-5, anti Ro/La antibodies, active disease and antiphospholipid antibodies. The most important issues of delaying pregnancy until there is quiescent disease, ensuring continued remission by continuation of drugs that are safe in pregnancy and adequately and promptly treating any flare of disease will be discussed. Adequate surveillance of the mother and fetus is imperative, but stratification of women is important to ensure that those with low risk pregnancies are not over medicated.

There is an understandable reluctance to prescribe drugs, particularly immunosuppressant drugs, in pregnancy in breast feeding mothers. However much harm can result if drugs are withdrawn, omitted or the dose reduced inappropriately. Active disease has an adverse effect on female fertility and time to pregnancy as well as impacting adversely on pregnancy outcomes.

Guidelines from the British Society of Rheumatology and EULAR have reviewed the safety data for antirheumatic drugs in pregnancy. These publications include recommendations for which drugs are compatible with pregnancy and during lactation. These guidelines should reduce errors of omission where important medication for disease control are discontinued prior to or in pregnancy and empower rheumatologists to help women to time their pregnancies during disease remission and with continuation of medications including biologics compatible with pregnancy.

REFERENCES:

Disclosure of Interests: Catherine Nelson-Piercy Consultant for: UCB, Speakers bureau: UCB

FRIDAY, 14 JUNE 2019

Immunosuppression in SSc – a matter of timing!

Jon Dieder, University of Erlangen-Nuremberg, Department of Internal Medicine 3, Erlangen, Germany

The pathophysiology of systemic sclerosis (SSc) is characterized by a cascade of microvascular injury with apoptosis of endothelial cells, Th2/M2 biased
**IMMUNOSUPPRESSION – ONE FITS ALL VS. INDIVIDUALIZED SELECTION?**

Marco Matucci-Cerinic. University of Florence, Division of Rheumatology AOUC, Florence 50139, Italy

Systemic sclerosis (SSc) is an autoimmune disease characterised by skin, vascular and internal organ involvement leading eventually to tissue fibrosis and atrophy. The best control of the disease is usually achieved in the early phase which is characterised by a diffuse tissue inflammation and vasculopathy, of the tissues. In this phase an immunosuppressive strategy can in fact lead to disease remission even if some cases may escape control and progress inoperably to fibrosis. Classically, the clinical profile of the patient needs to be achieved. The subset, the disease activity and the main clinical features should be defined in order to have the precise profile of the disease. The knowledge of the clinical conditions may therefore help in deciding the drug and shaping the therapeutic regimen and its intensity. Usually, the use of Cyclophosphamide (CYC) and Mycophenolate (MMF) may fit the necessity of the largest part of the SSc population. In practice, CYC may be employed as an induction treatment, either orally or intravenous, while MMF may be used as a maintenance therapy. Both drugs have been demonstrated to be useful in the treatment of SSc either on the cutaneous or on the lung involvement.

However, the most severe and refractory cases may be today considered for a hematopoietic stem cell transplantation (HSCT). In this case, an individualised selection is performed before a patient can be considered fit to receive this kind of therapeutic regimen. Therefore, the treatment is strictly individualised and only after having a thorough clinical evaluation the patient can be accepted for the systemic conditioning with high doses of CYC for bone marrow ablation. In conclusion, the treatment of SSc is today mainly centered on immunosuppression whose intensity must be decided and individualized according to the disease activity. New innovative targeted drugs are on the horizon in the effort to find the right immunosuppressive and anti-fibrotic therapeutic approach clinically tailored on the SSc patient.

**Disclosure of Interests:** Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen


**STEM CELL TRANSPLANTATION – ALL SCIENTIFIC QUESTIONS ANSWERED?**

Jacob M. van Laar. University Medical Center Utrecht, Netherlands

Hematopoietic stem cell transplantation (HSCT) currently is the only disease modifying treatment for patients with poor prognosis diffuse cutaneous systemic sclerosis (dcSSc) based on three controlled clinical trials (ASSIST, ASTIS, SCOT). Nevertheless uptake of this intensive treatment modality is slow in most countries, due to funding issues, lack of medical experience, and concerns over toxicities including the risk of transplant-related mortality (TRM). Over the years, safety of HSCT has improved and TRM has dropped due to more stringent patient selection and better supportive care. Nevertheless, risk of TRM remains a high-risk condition for HSCT, and even a minimum degree of risk remains unavoidable. The decision to opt for HSCT therefore requires a thorough discussion of potential benefits and possible risks with a patient and their family and ultimately hinges on shared decision making and informed consent. Apart from such clinical issues there are still plenty of scientific questions to be answered. First, should HSCT be offered as first-line immunosuppressive or chemotherapy in high-risk patients, or is it better to reserve HSCT as salvage-therapy for those who failed a course of routine immunosuppression or i.v. pulse cyclophosphamide? And if so, on the basis of what criteria should treatment intensity be stepped up? Second, how can patient selection be optimised so as to avoid transplanting dcSSc patients with little chance of responding? Third, is there a window of opportunity where the immune system can be rebooted? Last but not least, how can potentially eligible dcSSc patients get access to HSCT? The latter may be the most (de)pressing one, as HSCT is only available in a small number of centres. Until efficacious disease-modifying drugs with a better risk-benefit ratio become available, HSCT will continue to be the only therapeutic option to reverse the disease course in dcSSc patients.

**Disclosure of Interests:** Jacob M. van Laar Grant/research support from: Genentech, Consultant for: F. Hoffmann-La Roche


**PREDICTING SHORT-TERM FRACTURE RISK: CAN WE FORESEE THE (CLOSE) FUTURE?**

Nicholas Fuggle. University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom

A 60 year old female was under long-term follow-up for rheumatoid arthritis, for which she took methotrexate. Ten years previously she had been found to have a single vertebral fracture and her fracture risk, assessed using The WHO Fracture Risk Assessment Tool (FRAX®), was calculated to be a 13% risk of major osteoporotic fracture over the next 10 years. According to The National Osteoporosis Guideline Group (NOGG) recommendations, she underwent dual energy x-ray absorptiometry (DXA) which demonstrated a bone mineral density T-score of -1.7 at the femoral neck. Lifestyle, vitamin D and calcium intake were optimised and follow-up was arranged for 6 months.

Prior to her next appointment she fell and sustained a fracture of the distal radius. On fracture liaison review her FRAX® risk of fracture was 14% (rising due to an increased year of age) despite the recent change in clinical circumstances. This case serves to emphasise the clinical conundra associated with imminent fracture risk (the 2 years after a fracture when the patient is at a significantly higher risk of fracture) and the difficulties with the decision to treat.

**Disclosure of Interests:** None declared


**ONE FITS ALL VS. INDIVIDUALIZED SELECTION?**

Nicholas Fuggle. University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom

With an estimated 520,000 fragility fractures every year in the UK, delivering effective and efficient healthcare for this patient group has significant consequences for patients, families, the NHS, and society. A fragility fracture is a major risk factor for further fractures, and healthcare systems are now beginning to recognise the benefits of secondary fracture prevention. Despite this, less than 50% of patients receive effective secondary fracture prevention after a fragility fracture. This has led to national and international initiatives to improve clinical services by implementing fracture liaison services (FLSs). Successful funding of a new FLS is usually influenced by the number of fractures it is expected to prevent in the first few years after an index fracture. The expected number of fractures prevented is in turn determined by the baseline risk of subsequent fracture, the number of patients at high enough fracture risk to warrant anti-osteoporosis medication (AOM), and the degree of fracture risk reduction by AOMs. Underestimating fracture risk in the post-fracture period will lead to fewer expected fractures prevented and lower perceived benefit of the FLS by payers, and importantly also by patients, families, healthcare providers, and payers. Tools are available to determine the long-term risk of fracture based on patient factors, including previous fracture. Of these, FRAX and QFRact have been incorporated within UK NICE clinical guidance, and the FRAX-derived intervention threshold is used to guide recommendations for AOM in the NHS.

**Disclosure of Interests:** Cyprus Cooper Consultant for: Personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB.